Meropenem is Time-Dependent
Meropenem exhibits time-dependent bactericidal activity, meaning its efficacy depends on maintaining drug concentrations above the minimum inhibitory concentration (MIC) for a sufficient duration of the dosing interval, rather than achieving high peak concentrations.
Pharmacodynamic Mechanism
The FDA label explicitly states that "the percentage of time of a dosing interval that unbound plasma concentration of meropenem exceeds the meropenem minimum inhibitory concentration (MIC) against the infecting organism has been shown to best correlate with efficacy in animal and in vitro models of infection" 11. This is the defining characteristic of time-dependent killing.
The pharmacodynamic target for meropenem is maintaining free drug concentrations above the MIC for approximately 40% of the dosing interval (%fT>MIC ≥ 40%) 12. This stands in contrast to concentration-dependent antibiotics (like aminoglycosides or fluoroquinolones) where peak concentration relative to MIC (Cmax/MIC) or area under the curve (AUC/MIC) are the primary drivers of efficacy.
Clinical Implications for Dosing Strategy
Because meropenem is time-dependent, prolonged or continuous infusions may be superior to standard intermittent bolus dosing, particularly in critically ill patients or when treating organisms with elevated MICs:
Evidence for Prolonged/Continuous Infusion
The French critical care guidelines strongly support this approach. For infections with high MIC bacteria, continuous or prolonged infusions significantly increase the probability of achieving pharmacodynamic targets 3. Specifically:
- Continuous meropenem 3 g/24h achieved targets for bacteria with MIC ≤ 4 mg/L
- Intermittent dosing of the same daily dose only achieved targets for MIC ≤ 0.5 mg/L 3
A randomized controlled trial demonstrated that continuous infusion achieved superior microbiological success (90.6% vs 78.4%, P = 0.020) compared to intermittent bolus dosing, with shorter ICU stays and lower total drug requirements 4.
Important Caveats
However, the most recent large-scale evidence (the 2023 MERCY trial with 607 patients) found no difference in the composite outcome of mortality and emergence of resistant bacteria between continuous and intermittent administration 5. This suggests that while continuous infusion optimizes pharmacodynamics theoretically, the clinical benefit may be context-dependent.
Practical Dosing Approach
Standard dosing: 1-2 g IV every 8 hours as 30-minute infusions achieves adequate %fT>MIC for most susceptible organisms 11
Consider prolonged/continuous infusion when:
- Treating critically ill patients with septic shock 3
- Suspected or confirmed high MIC organisms (>2-4 mg/L) 3
- Inadequate clinical response to standard dosing
- Severe infections in immunocompromised patients 6
The key principle: Unlike dose-dependent antibiotics where you maximize the peak, with meropenem you maximize the time above MIC—either by giving more frequent doses, higher total daily doses, or extending the infusion duration.